Orchestra BioMed Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OBIO research report →
Range $10 – $13
Price Chart
About the company
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease.
- CEO
- David Hochman
- IPO
- 2020
- Employees
- 86
- HQ
- New Hope, PA, US
Get TickerSpark's AI analysis on OBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $325.15M
- P/E
- -5.48
- Fwd P/E
- 17.52
- PEG
- -0.09
- P/S
- 10.17
- P/B
- 11.78
- EV/EBITDA
- -5.72
- Div Yield
- 0.00%
- Gross Margin
- 99.32%
- Op Margin
- -181.36%
- Net Margin
- -184.60%
- ROE
- -125.93%
- ROIC
- -56.28%
Latest fiscal year · YoY change
- Revenue
- $33.48M+1169.2%
- Gross Profit
- $33.29M+1267.8%
- Op Income
- $-51,807,000
- Net Income
- $-52,701,000+13.6%
- EPS
- $-1.11+33.1%
- OCF Growth
- +3.2%
- FCF Growth
- +2.7%
- 52W High
- $5.78
- 52W Low
- $2.20
- 50D MA
- $4.10
- 200D MA
- $4.21
- Beta
- 0.50
- RSI (14)
- 75
- Avg Volume
- 343.06K
No earnings-call transcripts are available for OBIO yet.
- Free Float
- 68.9%
- Shares Outstanding
- 59.88M
- Float Shares
- 41.26M
of shares held by institutions
66 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.60M | ▲ 122.68K |
| Amh Equity Ltd | 166.00K | ▲ 166.00K |
| Cubist Systematic Strategies, LLC | 77.89K | ▲ 60.18K |
| Lasry Marc | 60.87K | 0 |
| Two Sigma Advisers, LP | 27.10K | ▲ 27.10K |
| Point72 Asia (Singapore) Pte. Ltd. | 9.35K | ▼ 9.36K |
| Point72 (Difc) Ltd | 272 | ▼ 82 |
Held by 78 ETFs
Biggest fund positions in OBIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 12, 26 | Pacitti David | other | 3,761 |
| Aug 12, 26 | Fain Eric S | other | 5,145 |
| Aug 12, 26 | Mack John Prosper | other | 4,885 |
| Aug 12, 26 | Cleary Chris | other | 4,238 |
| Aug 3, 26 | Sherman Darren | sell | 15,000 |
| Jul 1, 26 | Sherman Darren | sell | 15,000 |
| Jun 23, 26 | Fain Eric S | other | 17,327 |
| Jun 24, 26 | Fain Eric S | other | 4,261 |
| Jun 23, 26 | Fain Eric S | other | 21,277 |
| Jun 23, 26 | Pacitti David | other | 17,327 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OBIO coverage
Recent articles, reports, and earnings notes.
No research on OBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OBIO report →Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
globenewswire.com · Aug 20
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates
zacks.com · Aug 10
Affinity Asset Advisors LLC Lowers Holdings in Orchestra BioMed Holdings, Inc. $OBIO
defenseworld.net · Jul 25
Orchestra BioMed: Nearing The First Of Two Pivotal Readouts
seekingalpha.com · Jul 22
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
globenewswire.com · Jun 29
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jun 2
Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
globenewswire.com · May 19
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
zacks.com · May 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.